10th RWE, Market Access, Pricing & Reimbursement
Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines
Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross
Independence Blue Cross
RWE, Market Access, Pricing & Reimbursement 2023 Americas
On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.
The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across the globe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, US, national
governments and regional authorities.
RWE is playing an increasingly critical role in supporting every aspect of successful evidence-generation programs and presents immense possibilities, it also brings substantial challenges that continue to cast shadows on its validity. Concerns such as data viases, data quality, and the possible false results due to data mining, progress have diminished primarily.
The upcoming 2023 RWE, Market Access, Pricing and Reimbursement World Congress Americas will present a dynamic approach to key trends and insights on market access, health technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.
This year, we are putting together an agenda that addresses “Defining Value to Obtain Informed Evidence Optimizing Patient Access to Medicines”. We are gathering together high caliber expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.
We look forward to welcoming you to the RWE, MAPR 2023 congress!
Gain insights on:
Who Should Attend
Jason Noto, Senior Vice President, US Market Access, AVEO Oncology
Danielle Bargo, Director, Real World Evidence and HEOR, Eisai
No Spam - You will only receive relevant information on Real World Evidence, Market Access, Pricing & Reimbursement, and events updates.
Take Advantage of the Super Early Bird Discount. Group Discounts Also Available.